UNSPSC 51281802: Aclarubicin or aclacinomycin A

This classification denotes an aclacinomycin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74KXF8I502. European Medicines Agency schedules Aclarubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05243MIG. Aclarubicin generally arises in the molecular formula C42H53NO15. The term ACLARUBICIN is an International Non-Proprietary Name or INN. ACLARUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

SMILES: O(C1CC(O)(C(C2C1C(O)C1C(C2)C(=O)C2C(C1=O)C(O)CCC2)C(=O)OC)CC)C1OC(C(OC2OC(C(OC3OC(C(=O)CC3)C)C(O)C2)C)C(N(C)C)C1)C.

UNSPSC 51281802 Aclarubicin or aclacinomycin A is a Commodity code for a specific pharmaceutical active ingredient, but recent state and local solicitations tagged under this code show minimal alignment with its nominal scope. The code appears in opportunities for naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which involve aclarubicin or aclacinomycin A, a chemotherapy agent used in oncology practice. State and local procurement offices are using this code as a catch-all pharmaceutical taxonomy entry rather than for its intended narrow purpose, creating a classification mismatch that limits its utility for tracking genuine demand for the specific active ingredient.

Solicitations under this code span county health departments, state HHS commissions, municipal fire departments, and multistate cooperative purchasing alliances across Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually; the City of Tampa's IFB 26-P-00145 (posted March 25, 2026; due March 13, 2026) for medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000, designated as a sheltered market opportunity with a 5 percent bid discount for certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities. The code shows no recent relevant activity for aclarubicin or aclacinomycin A procurement.